Double SCN5A mutation underlying asymptomatic Brugada syndrome

Hisataka Yokoi, Naomasa Makita, Koji Sasaki, Yasuhiro Takagi, Yasuo Okumura, Tetsuo Nishino, Takeru Makiyama, Akira Kitabatake, Minoru Horie, Ichiro Watanabe, Hiroyuki Tsutsui

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives: The purpose of this study was to identify risk markers in patients with Brugada syndrome. Background: Patients with Brugada syndrome who experience syncope or aborted sudden death are at high risk for recurrent lethal arrhythmias. The prognosis and therapeutic approaches in asymptomatic individuals with a Brugada-type ECG (asymptomatic Brugada syndrome) are controversial. Methods: We genetically screened 30 asymptomatic probands (29 men and 1 woman; mean age 47.1 years) exhibiting a spontaneous Brugada-type ECG. Family members of patients with Brugada syndrome were excluded from the study. Results: Twenty-nine of 30 patients (96.7%) remained symptom-free for at least 3 years. One patient (case 1) with a family history of sudden death died suddenly during sleep. Ventricular fibrillation was induced by programmed electrical stimulation in 14 of 18 subjects (78%), but none of these 18 subjects developed spontaneous ventricular arrhythmias. Genetic screening failed to identify SCN5A mutations in most cases but demonstrated a novel double missense mutation (K1527R and A1569P) located on the same allele in another asymptomatic subject (case 2). Heterologously expressed mutant Na channels exhibited a negative shift of steady-state inactivation (9.2 mV) and enhanced slow inactivation, suggesting this individual harbors a subclinical channel dysfunction compatible with symptomatic Brugada syndrome. Conclusions: Asymptomatic individuals with a Brugada-type ECG generally have a better prognosis than their symptomatic counterparts, but a subgroup of these individuals may have a poor prognosis. Severe Na channel dysfunction as a result of SCN5A mutations may not be sufficient to cause symptoms or arrhythmias in patients with Brugada syndrome, suggesting unknown factors or modifier genes influence arrhythmogenesis.

Original languageEnglish
Pages (from-to)285-292
Number of pages8
JournalHeart Rhythm
Volume2
Issue number3
DOIs
Publication statusPublished - Mar 1 2005
Externally publishedYes

Fingerprint

Brugada Syndrome
Mutation
Cardiac Arrhythmias
Electrocardiography
Sudden Death
Modifier Genes
Syncope
Genetic Testing
Ventricular Fibrillation
Missense Mutation
Electric Stimulation
Sleep
Alleles

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Yokoi, H., Makita, N., Sasaki, K., Takagi, Y., Okumura, Y., Nishino, T., ... Tsutsui, H. (2005). Double SCN5A mutation underlying asymptomatic Brugada syndrome. Heart Rhythm, 2(3), 285-292. https://doi.org/10.1016/j.hrthm.2004.11.022

Double SCN5A mutation underlying asymptomatic Brugada syndrome. / Yokoi, Hisataka; Makita, Naomasa; Sasaki, Koji; Takagi, Yasuhiro; Okumura, Yasuo; Nishino, Tetsuo; Makiyama, Takeru; Kitabatake, Akira; Horie, Minoru; Watanabe, Ichiro; Tsutsui, Hiroyuki.

In: Heart Rhythm, Vol. 2, No. 3, 01.03.2005, p. 285-292.

Research output: Contribution to journalArticle

Yokoi, H, Makita, N, Sasaki, K, Takagi, Y, Okumura, Y, Nishino, T, Makiyama, T, Kitabatake, A, Horie, M, Watanabe, I & Tsutsui, H 2005, 'Double SCN5A mutation underlying asymptomatic Brugada syndrome', Heart Rhythm, vol. 2, no. 3, pp. 285-292. https://doi.org/10.1016/j.hrthm.2004.11.022
Yokoi H, Makita N, Sasaki K, Takagi Y, Okumura Y, Nishino T et al. Double SCN5A mutation underlying asymptomatic Brugada syndrome. Heart Rhythm. 2005 Mar 1;2(3):285-292. https://doi.org/10.1016/j.hrthm.2004.11.022
Yokoi, Hisataka ; Makita, Naomasa ; Sasaki, Koji ; Takagi, Yasuhiro ; Okumura, Yasuo ; Nishino, Tetsuo ; Makiyama, Takeru ; Kitabatake, Akira ; Horie, Minoru ; Watanabe, Ichiro ; Tsutsui, Hiroyuki. / Double SCN5A mutation underlying asymptomatic Brugada syndrome. In: Heart Rhythm. 2005 ; Vol. 2, No. 3. pp. 285-292.
@article{ecd4854516c042388a646fbd0d5abe32,
title = "Double SCN5A mutation underlying asymptomatic Brugada syndrome",
abstract = "Objectives: The purpose of this study was to identify risk markers in patients with Brugada syndrome. Background: Patients with Brugada syndrome who experience syncope or aborted sudden death are at high risk for recurrent lethal arrhythmias. The prognosis and therapeutic approaches in asymptomatic individuals with a Brugada-type ECG (asymptomatic Brugada syndrome) are controversial. Methods: We genetically screened 30 asymptomatic probands (29 men and 1 woman; mean age 47.1 years) exhibiting a spontaneous Brugada-type ECG. Family members of patients with Brugada syndrome were excluded from the study. Results: Twenty-nine of 30 patients (96.7{\%}) remained symptom-free for at least 3 years. One patient (case 1) with a family history of sudden death died suddenly during sleep. Ventricular fibrillation was induced by programmed electrical stimulation in 14 of 18 subjects (78{\%}), but none of these 18 subjects developed spontaneous ventricular arrhythmias. Genetic screening failed to identify SCN5A mutations in most cases but demonstrated a novel double missense mutation (K1527R and A1569P) located on the same allele in another asymptomatic subject (case 2). Heterologously expressed mutant Na channels exhibited a negative shift of steady-state inactivation (9.2 mV) and enhanced slow inactivation, suggesting this individual harbors a subclinical channel dysfunction compatible with symptomatic Brugada syndrome. Conclusions: Asymptomatic individuals with a Brugada-type ECG generally have a better prognosis than their symptomatic counterparts, but a subgroup of these individuals may have a poor prognosis. Severe Na channel dysfunction as a result of SCN5A mutations may not be sufficient to cause symptoms or arrhythmias in patients with Brugada syndrome, suggesting unknown factors or modifier genes influence arrhythmogenesis.",
author = "Hisataka Yokoi and Naomasa Makita and Koji Sasaki and Yasuhiro Takagi and Yasuo Okumura and Tetsuo Nishino and Takeru Makiyama and Akira Kitabatake and Minoru Horie and Ichiro Watanabe and Hiroyuki Tsutsui",
year = "2005",
month = "3",
day = "1",
doi = "10.1016/j.hrthm.2004.11.022",
language = "English",
volume = "2",
pages = "285--292",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Double SCN5A mutation underlying asymptomatic Brugada syndrome

AU - Yokoi, Hisataka

AU - Makita, Naomasa

AU - Sasaki, Koji

AU - Takagi, Yasuhiro

AU - Okumura, Yasuo

AU - Nishino, Tetsuo

AU - Makiyama, Takeru

AU - Kitabatake, Akira

AU - Horie, Minoru

AU - Watanabe, Ichiro

AU - Tsutsui, Hiroyuki

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Objectives: The purpose of this study was to identify risk markers in patients with Brugada syndrome. Background: Patients with Brugada syndrome who experience syncope or aborted sudden death are at high risk for recurrent lethal arrhythmias. The prognosis and therapeutic approaches in asymptomatic individuals with a Brugada-type ECG (asymptomatic Brugada syndrome) are controversial. Methods: We genetically screened 30 asymptomatic probands (29 men and 1 woman; mean age 47.1 years) exhibiting a spontaneous Brugada-type ECG. Family members of patients with Brugada syndrome were excluded from the study. Results: Twenty-nine of 30 patients (96.7%) remained symptom-free for at least 3 years. One patient (case 1) with a family history of sudden death died suddenly during sleep. Ventricular fibrillation was induced by programmed electrical stimulation in 14 of 18 subjects (78%), but none of these 18 subjects developed spontaneous ventricular arrhythmias. Genetic screening failed to identify SCN5A mutations in most cases but demonstrated a novel double missense mutation (K1527R and A1569P) located on the same allele in another asymptomatic subject (case 2). Heterologously expressed mutant Na channels exhibited a negative shift of steady-state inactivation (9.2 mV) and enhanced slow inactivation, suggesting this individual harbors a subclinical channel dysfunction compatible with symptomatic Brugada syndrome. Conclusions: Asymptomatic individuals with a Brugada-type ECG generally have a better prognosis than their symptomatic counterparts, but a subgroup of these individuals may have a poor prognosis. Severe Na channel dysfunction as a result of SCN5A mutations may not be sufficient to cause symptoms or arrhythmias in patients with Brugada syndrome, suggesting unknown factors or modifier genes influence arrhythmogenesis.

AB - Objectives: The purpose of this study was to identify risk markers in patients with Brugada syndrome. Background: Patients with Brugada syndrome who experience syncope or aborted sudden death are at high risk for recurrent lethal arrhythmias. The prognosis and therapeutic approaches in asymptomatic individuals with a Brugada-type ECG (asymptomatic Brugada syndrome) are controversial. Methods: We genetically screened 30 asymptomatic probands (29 men and 1 woman; mean age 47.1 years) exhibiting a spontaneous Brugada-type ECG. Family members of patients with Brugada syndrome were excluded from the study. Results: Twenty-nine of 30 patients (96.7%) remained symptom-free for at least 3 years. One patient (case 1) with a family history of sudden death died suddenly during sleep. Ventricular fibrillation was induced by programmed electrical stimulation in 14 of 18 subjects (78%), but none of these 18 subjects developed spontaneous ventricular arrhythmias. Genetic screening failed to identify SCN5A mutations in most cases but demonstrated a novel double missense mutation (K1527R and A1569P) located on the same allele in another asymptomatic subject (case 2). Heterologously expressed mutant Na channels exhibited a negative shift of steady-state inactivation (9.2 mV) and enhanced slow inactivation, suggesting this individual harbors a subclinical channel dysfunction compatible with symptomatic Brugada syndrome. Conclusions: Asymptomatic individuals with a Brugada-type ECG generally have a better prognosis than their symptomatic counterparts, but a subgroup of these individuals may have a poor prognosis. Severe Na channel dysfunction as a result of SCN5A mutations may not be sufficient to cause symptoms or arrhythmias in patients with Brugada syndrome, suggesting unknown factors or modifier genes influence arrhythmogenesis.

UR - http://www.scopus.com/inward/record.url?scp=20044374511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044374511&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2004.11.022

DO - 10.1016/j.hrthm.2004.11.022

M3 - Article

C2 - 15851320

AN - SCOPUS:20044374511

VL - 2

SP - 285

EP - 292

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 3

ER -